Your Messages Inbox
Your Article Summary
See Latest ArticlesDronedarone: An antiarrhythmic agent for the management of atrial fibrillation and atrial flutter
Formulary , 02/11/09
Coleman CI et al. - The results of an additional trial suggest that dronedarone should not be used in patients with severe heart failure, as these patients demonstrated an increased mortality risk with dronedarone treatment. Worsening renal function has also been associated with dronedarone, but the clinical relevance of this is a matter of some debate. Dronedarone is currently pending FDA approval; the agent was granted priority review in August 2008.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Article Search
Sponsor